NO20024867L - Fremgangsmåte og preparat for behandling av kreft ved administrering av apoptoseinduserende kjemoterapeutiske midler - Google Patents

Fremgangsmåte og preparat for behandling av kreft ved administrering av apoptoseinduserende kjemoterapeutiske midler

Info

Publication number
NO20024867L
NO20024867L NO20024867A NO20024867A NO20024867L NO 20024867 L NO20024867 L NO 20024867L NO 20024867 A NO20024867 A NO 20024867A NO 20024867 A NO20024867 A NO 20024867A NO 20024867 L NO20024867 L NO 20024867L
Authority
NO
Norway
Prior art keywords
administration
preparation
treating cancer
chemotherapeutic agents
apoptosis inducing
Prior art date
Application number
NO20024867A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024867D0 (no
Inventor
Moshe Flashner-Barak
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20024867D0 publication Critical patent/NO20024867D0/no
Publication of NO20024867L publication Critical patent/NO20024867L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20024867A 2000-04-10 2002-10-09 Fremgangsmåte og preparat for behandling av kreft ved administrering av apoptoseinduserende kjemoterapeutiske midler NO20024867L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19592000P 2000-04-10 2000-04-10
PCT/US2001/011688 WO2001076567A1 (en) 2000-04-10 2001-04-10 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents

Publications (2)

Publication Number Publication Date
NO20024867D0 NO20024867D0 (no) 2002-10-09
NO20024867L true NO20024867L (no) 2002-12-06

Family

ID=22723363

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024867A NO20024867L (no) 2000-04-10 2002-10-09 Fremgangsmåte og preparat for behandling av kreft ved administrering av apoptoseinduserende kjemoterapeutiske midler

Country Status (19)

Country Link
US (1) US20020041888A1 (pl)
EP (1) EP1274404A1 (pl)
JP (1) JP2004507451A (pl)
KR (1) KR20030008368A (pl)
CN (1) CN1438882A (pl)
AU (1) AU2001253334A1 (pl)
BR (1) BR0110150A (pl)
CA (1) CA2406484A1 (pl)
CZ (1) CZ20023333A3 (pl)
EA (1) EA200201068A1 (pl)
HU (1) HUP0302296A2 (pl)
IL (1) IL152180A0 (pl)
MX (1) MXPA02009984A (pl)
NO (1) NO20024867L (pl)
PL (1) PL366035A1 (pl)
SK (1) SK14452002A3 (pl)
WO (1) WO2001076567A1 (pl)
YU (1) YU77002A (pl)
ZA (1) ZA200208167B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
CA2482941A1 (en) * 2002-04-26 2003-11-06 Teva Pharmaceutical Industries Ltd. Microparticle pharmaceutical compositions for intratumoral delivery
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
AU2005299748B2 (en) * 2004-10-21 2009-04-09 Tgel Bio Co., Ltd In situ controlled release drug delivery system
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2601067A1 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
CA2646156C (en) 2006-03-22 2016-05-24 Medigene Ag Treatment of triple receptor negative breast cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
EP3925625A1 (en) * 2011-01-09 2021-12-22 ANP Technologies, Inc. Hydrophobic molecule-induced branched polymer aggregates and their use
WO2021138646A1 (en) 2020-01-03 2021-07-08 Privo Technologies, Inc. Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins

Also Published As

Publication number Publication date
AU2001253334A1 (en) 2001-10-23
ZA200208167B (en) 2004-02-10
CN1438882A (zh) 2003-08-27
PL366035A1 (pl) 2005-01-24
KR20030008368A (ko) 2003-01-25
MXPA02009984A (es) 2004-09-10
CA2406484A1 (en) 2001-10-18
US20020041888A1 (en) 2002-04-11
CZ20023333A3 (cs) 2003-06-18
WO2001076567A1 (en) 2001-10-18
NO20024867D0 (no) 2002-10-09
IL152180A0 (en) 2003-05-29
JP2004507451A (ja) 2004-03-11
SK14452002A3 (sk) 2003-07-01
EA200201068A1 (ru) 2003-12-25
HUP0302296A2 (hu) 2003-10-28
BR0110150A (pt) 2004-04-27
YU77002A (sh) 2005-09-19
EP1274404A1 (en) 2003-01-15

Similar Documents

Publication Publication Date Title
CY2020005I1 (el) Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση καρκινου του παγκρεατος
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
NO20024867D0 (no) Fremgangsmåte og preparat for behandling av kreft ved administrering av apoptoseinduserende kjemoterapeutiske midler
NO20033883L (no) Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer
EE05481B1 (et) Kinasoliini derivaadid kasvajate raviks
NO20033684D0 (no) Behandling av motstandsdyktige tumorer ved anvendelse av epotilonderivater
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
CY2013011I2 (el) Μεθοδος χορηγησης διφωσφονικων
NO20035426L (no) Fremgangsmate ved administrering av anti-TNF-D-antistoff
NO20034780L (no) Antiangiogenisk kombinasjonsterapi for behandling av kreft
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
AU2002364211A1 (en) Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
NO20030748L (no) Prodruger av betulinsyrederivater for behandlingen av kreft og HIV
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
EP1320376A4 (en) TREATMENT OF PROSTATE CANCER
NO20033429L (no) Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK)
NO20012367D0 (no) Behandling av tumorer ved administrering av veksthormonfrigjörende forbindelser og deres antagonister
NO20033341D0 (no) Metoder for administrering av epothilone-analoger for behandling av kreft
NO994426D0 (no) Nye karboksylsyrederivater, deres fremstilling og anvendelse ved behandling av kreft
NO20023737L (no) Fremgangsmåte og preparater for behandling av en inflammatorisk lidelse
NO20031583L (no) Fremgangsmåte for mikrobölgeovn-behandling av ferdigpakket farget popkorn
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
EP1423118A4 (en) METHOD AND COMPOSITION FOR CANCER TREATMENT
NO20015162L (no) Fremgangsmåte for behandling av nevrodegenerering

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application